Diabetes Self-Management Blog

By now, you have probably heard of the Action to Control Cardiovascular Risk in Diabetes, or ACCORD, trial. (If not, you can check out “The ACCORD Trial Findings: What You Should Know” for a full report.)

This study, which was initiated in 1999, involves people who have Type 2 diabetes and a history of or high risk of cardiovascular disease. There were originally three branches of the trial, concentrating on blood glucose control, blood pressure control, and cholesterol and triglyceride control, respectively. The branch that focused on blood glucose control sought to compare an intensive treatment group (in which people aimed to achieve an HbA1c level below 6.0%) to a standard treatment group (in which people aimed for an HbA1c level from 7.0% to 7.9%) to determine which strategy more effectively reduced the rate of cardiovascular events. However, due to concerns about an unexpected, slightly increased rate of death among those who were tightly controlling their blood glucose, the intensive treatment arm of the trial was halted 18 months earlier than scheduled.

Not surprisingly, this outcome has led to a lot of discussion in the diabetes blogging community. Several bloggers took issue with the manner in which many mainstream media outlets presented the information, noting that the data do not apply to a large number of people with diabetes. For example, as Bernard Farrell at Bernard’s Diabetes Blog points out, the findings of the ACCORD trial don’t pertain to people with Type 1 diabetes. And as Amy Tenderich at Diabetes Mine notes, the results also don’t apply to many with Type 2 diabetes, such as younger people who are not at high risk of heart disease. Over at Scott’s Web Log, diabetes blogger Scott Strumello expresses hope that this situation will call attention to what he views as a “fixation on glycemic control above all else [that] has been detrimental to patient health.”

The American Diabetes Association also weighed in on the matter, advising people who have diabetes and cardiovascular disease or multiple risk factors for cardiovascular disease to consult with their health-care team about their treatment goals.

For more information about the ACCORD trial, visit the study’s official Web site or the “Questions and Answers” page of the National Heart, Lung, and Blood Institute, the sponsor of the trial.

This blog entry was written by Assistant Editor Diane Fennell.

POST A COMMENT       
  

We are currently experiencing technical difficulties with our commenting system. Thank you for your patience as we work to resolve them.


What We're Reading
How Much Do You Know About Diabetes and Alcohol? (11/26/14)
Diabetes Self-Management Readers' Poll: Thanksgiving (11/27/14)
JDRF 2015 Children's Congress (11/17/14)
Diabetes Self-Management Readers' Poll: Support Groups (11/20/14)

Diabetes Research
A Diabetes Cure in Mice (11/13/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)

Diabetes News
Mediterranean Diet May Benefit Kidneys (11/06/14)
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
FDA Approves Remote Glucose-Monitoring Technology (10/24/14)
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.